Medpace Holdings, Inc. Reports Second Quarter 2021 Results

Rhea-AI Summary

Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 35.8% increase in revenue for Q2 2021, reaching $278.3 million. The company's backlog grew 29.8% to $1.7 billion, and net new business awards hit $387.6 million, yielding a book-to-bill ratio of 1.39x. GAAP net income rose to $39.9 million or $1.06 per diluted share, representing a net income margin of 14.3%. The company forecasts 2021 revenue between $1.110 billion and $1.150 billion and GAAP net income between $162.5 million and $169.5 million.

Positive

• Revenue increased 35.8% to $278.3 million.
• Backlog grew 29.8% to $1.7 billion.
• Net new business awards were $387.6 million, 1.39x book-to-bill ratio.
• GAAP net income rose to $39.9 million, $1.06 per diluted share.
• Forecasted 2021 revenue range of $1.110 billion to $1.150 billion.

Negative

• Total direct costs increased to $203.6 million from $148.4 million.
• SG&A expenses rose to $27.0 million from $21.9 million.

Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the second quarter ended June 30, 2021.

Second Quarter 2021 Financial Results

Revenue for the three months ended June 30, 2021 increased 35.8% to $278.3 million, compared to $205.0 million for the comparable prior-year period. On a constant currency organic basis, revenue for the second quarter of 2021 increased 34.4% compared to the second quarter of 2020.

Backlog as of June 30, 2021 grew 29.8% to $1.7 billion from $1.3 billion as of June 30, 2020. Net new business awards were $387.6 million, representing a net book-to-bill ratio of 1.39x for the second quarter of 2021, as compared to $254.1 million for the comparable prior-year period. The Company calculates the net book-to-bill ratio by dividing net new business awards by revenue.

For the second quarter of 2021, total direct costs were $203.6 million, compared to total direct costs of $148.4 million in the second quarter of 2020. Selling, general and administrative (SG&A) expenses were $27.0 million in the second quarter of 2021, compared to SG&A expenses of $21.9 million in the second quarter of 2020.

GAAP net income for the second quarter of 2021 was $39.9 million, or $1.06 per diluted share, versus GAAP net income of $24.1 million, or $0.64 per diluted share, for the second quarter of 2020. This resulted in a net income margin of 14.3% and 11.8% for the second quarter of 2021 and 2020, respectively.

EBITDA for the second quarter of 2021 increased 36.9% to $47.9 million, or 17.2% of revenue, compared to $35.0 million, or 17.1% of revenue, for the comparable prior-year period. On a constant currency basis, EBITDA for the second quarter of 2021 increased 41.5% from the second quarter of 2020.

A reconciliation of the Company’s non-GAAP financial measures, including EBITDA and EBITDA margin to the corresponding GAAP measures is provided below.

Balance Sheet and Liquidity

The Company’s Cash and cash equivalents were $339.0 million at June 30, 2021, and the Company generated $62.8 million in cash flow from operating activities during the second quarter of 2021. During the second quarter of 2021, the Company repurchased approximately 0.34 million shares at an average price of $163.61 per share for a total of $56.1 million. The Company had $196.4 million remaining under its authorized share repurchase program at the end of the quarter.

Financial Guidance

The Company forecasts 2021 revenue in the range of $1.110 billion to $1.150 billion, representing growth of 19.9% to 24.2% over 2020 revenue of $925.9 million. GAAP net income for full year 2021 is forecasted in the range of $162.5 million to $169.5 million. Additionally, full year 2021 EBITDA is expected in the range of $205.0 million to $215.0 million. Based on forecasted 2021 revenue of $1.110 billion to $1.150 billion and GAAP net income of $162.5 million to $169.5 million, diluted earnings per share (GAAP) is forecasted in the range of $4.31 to $4.50. This guidance assumes a full year 2021 tax rate of 11.0% to 12.0% and does not reflect the potential impact of any share repurchases the Company may make pursuant to the share repurchase program after June 30, 2021.

Conference Call Details

Medpace will host a conference call at 9:00 a.m. ET, Tuesday, July 27, 2021, to discuss its second quarter 2021 results.

To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 4092073.

To access the conference call via webcast, visit the “Investors” section of Medpace’s website at medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A supplemental slide presentation will also be available at the “Investors” section of Medpace’s website prior to the start of the call.

A recording of the call will be available until Tuesday, August 3, 2021. To hear this recording, dial 855-859-2056 (domestic) or 404-537-3406 (international) using the passcode 4092073.

About Medpace

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace’s mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 4,100 people across 40 countries as of June 30, 2021.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our forecasted financial results, the anticipated impact of the coronavirus pandemic on our business, and the effective tax rate used for non-GAAP adjustment purposes. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “guidance,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” “forecast,” “may,” “could,” “likely,” “anticipate,” “project,” “goal,” “objective,” “potential,” “range,” “estimate,” “preliminary,” similar expressions, and variations or negatives of these words.

These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our financial condition, actual results, performance (including share price performance), or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the potential loss, delay or non-renewal of our contracts, or the non-payment by customers for services we have performed; the failure to convert backlog to revenue at our present or historical conversion rate(s); the failure to maintain or generate new business awards; fluctuation in our results between fiscal quarters and years; the risks and uncertainties related to disruptions to or reductions in business operations or prospects due to pandemics, epidemics, widespread health emergencies, or outbreaks of infectious diseases such as coronavirus disease COVID-19; decreased operating margins due to increased pricing pressure or other factors; our failure to perform our services in accordance with contractual requirements, government regulations and ethical considerations; the impact of underpricing our contracts, overrunning our cost estimates or failing to receive approval for or experiencing delays with documentation of change orders; our failure to increase our market share, grow our business, successfully execute our growth strategies or manage our growth effectively; the impact of a failure to retain key executives or other personnel or recruit experienced personnel; the risks associated with our information systems infrastructure, including potential cybersecurity breaches and other disruptions which could compromise patient information or our information; adverse results from customer or therapeutic area concentration; the risks associated with doing business internationally, including the effects of tariffs and trade wars; the risks associated with the Foreign Corrupt Practices Act and other anti-corruption laws; future net losses; the impact of changes in tax laws and regulations; our failure to attract suitable investigators and patients to our clinical trials; the liability risks associated with our research and development services, including risks of liability resulting from harm to patients; inadequate insurance coverage for our operations and indemnification obligations; fluctuations in exchange rates; general economic conditions in the markets in which we operate, including financial market conditions; the impact of a natural disaster or other catastrophic event; negative outsourcing trends in the biopharmaceutical industry and a reduction in aggregate expenditures and research and development budgets; our inability to compete effectively with other CROs; the impact of healthcare reform; the impact of consolidation in the biopharmaceutical industry; our failure to comply with federal, state and foreign healthcare laws; the effect of current and proposed laws and regulations regarding the protection of personal data; our potential involvement in costly intellectual property lawsuits; actions by regulatory authorities or customers to limit the scope of indications related to or withdraw an approved drug, biologic or medical device from the market; the impact of industry-wide reputational harm to CROs; and the effect of the U.K.’s withdrawal from the EU, which could have implications on our research, commercial and general business operations in the U.K. and the EU.

These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. If known or unknown risks or uncertainties materialize or if underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events, developments or circumstances cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Non-GAAP Financial Measures

Certain financial measures presented in this press release, such as EBITDA and EBITDA margin, are not recognized under generally accepted accounting principles in the United States of America, or U.S. GAAP. Management uses EBITDA and EBITDA margin or comparable metrics as a measurement used in evaluating our operating performance on a consistent basis, as a consideration to assess incentive compensation for our employees, for planning purposes, including the preparation of our internal annual operating budget, and to evaluate the performance and effectiveness of our operational strategies.

EBITDA and EBITDA margin have important limitations as analytical tools and you should not consider them in isolation, or as a substitute for, analysis of our results as reported under U.S. GAAP. See the condensed consolidated financial statements included elsewhere in this release for our U.S. GAAP results. Additionally, for reconciliations of EBITDA and EBITDA margin to our closest reported U.S. GAAP measures, refer to the appendix of this press release.

We believe that EBITDA and EBITDA margin are useful to provide additional information to investors about certain material non-cash and non-recurring items. While we believe these financial measures are commonly used by investors to evaluate our performance and that of our competitors, because not all companies use identical calculations, this presentation of EBITDA and EBITDA margin may not be comparable to other similarly titled measures of other companies and should not be considered as an alternative to performance measures derived in accordance with U.S. GAAP. EBITDA is calculated as net income attributable to Medpace Holdings, Inc. before income tax expense, interest expense, net, depreciation and amortization. EBITDA margin is calculated by dividing EBITDA by Revenue, net for each period. Our presentation of EBITDA and EBITDA margin should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

MEDPACE HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Amounts in thousands, except per share amounts)		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2021				2020				2021				2020
Revenue, net		$	278,293			$	204,995			$	538,258			$	435,874
Operating expenses:
Direct service costs, excluding depreciation and amortization			108,233				86,625				209,620				175,420
Reimbursed out-of-pocket expenses			95,409				61,733				175,560				138,739
Total direct costs			203,642				148,358				385,180				314,159
Selling, general and administrative			26,973				21,855				52,711				46,979
Depreciation			3,951				2,674				7,763				5,127
Amortization			1,279				1,980				2,557				3,977
Total operating expenses			235,845				174,867				448,211				370,242
Income from operations			42,448				30,128				90,047				65,632
Other income, net:
Miscellaneous income, net			265				239				1,189				856
Interest (expense) income, net			(27	)			(5	)			(41	)			352
Total other income, net			238				234				1,148				1,208
Income before income taxes			42,686				30,362				91,195				66,840
Income tax provision			2,752				6,258				7,955				13,782
Net income		$	39,934			$	24,104			$	83,240			$	53,058
Net income per share attributable to common shareholders:
Basic		$	1.11			$	0.68			$	2.32			$	1.48
Diluted		$	1.06			$	0.64			$	2.20			$	1.40
Weighted average common shares outstanding:
Basic			35,894				35,386				35,825				35,705
Diluted			37,714				37,328				37,737				37,680

MEDPACE HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(Amounts in thousands, except share amounts)
		As Of
		June 30,				December 31,
		2021				2020
ASSETS
Current assets:
Cash and cash equivalents		$	339,009			$	277,766
Accounts receivable and unbilled, net			161,489				160,962
Prepaid expenses and other current assets			49,602				34,923
Total current assets			550,100				473,651
Property and equipment, net			86,195				85,017
Operating lease right-of-use assets			110,730				113,809
Goodwill			662,396				662,396
Intangible assets, net			43,917				46,474
Deferred income taxes			540				536
Other assets			15,830				8,794
Total assets		$	1,469,708			$	1,390,677
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	23,326			$	26,552
Accrued expenses			145,847				134,367
Advanced billings			282,217				255,664
Other current liabilities			21,217				23,527
Total current liabilities			472,607				440,110
Operating lease liabilities			112,850				115,143
Deferred income tax liability			16,242				13,551
Other long-term liabilities			16,127				16,094
Total liabilities			617,826				584,898
Commitments and contingencies
Shareholders’ equity:
Preferred stock - $0.01 par-value; 5,000,000 shares authorized; no shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively			-				-
Common stock - $0.01 par-value; 250,000,000 shares authorized at June 30, 2021 and December 31, 2020, respectively; 35,819,012 and 35,519,989 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively			358				355
Treasury stock - 185,000 shares at June 30, 2021 and December 31, 2020, respectively			(5,578	)			(5,578	)
Additional paid-in capital			716,547				695,904
Retained earnings			142,315				115,229
Accumulated other comprehensive loss			(1,760	)			(131	)
Total shareholders’ equity			851,882				805,779
Total liabilities and shareholders’ equity		$	1,469,708			$	1,390,677

MEDPACE HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(Amounts in thousands)		Six Months Ended
		June 30,
		2021				2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income		$	83,240			$	53,058
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation			7,763				5,127
Amortization			2,557				3,977
Stock-based compensation expense			6,441				8,061
Noncash lease expense			7,899				6,288
Deferred income tax provision			2,667				2,416
Amortization and adjustment of deferred credit			(334	)			(356	)
Other			131				(265	)
Changes in assets and liabilities:
Accounts receivable and unbilled, net			(353	)			28,524
Prepaid expenses and other current assets			(14,889	)			(860	)
Accounts payable			(270	)			(7,173	)
Accrued expenses			11,937				(5,933	)
Advanced billings			26,553				3,094
Lease liabilities			(7,956	)			(4,933	)
Other assets and liabilities, net			(5,306	)			2,390
Net cash provided by operating activities			120,080				93,415
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment expenditures			(12,515	)			(14,885	)
Other			(3,133	)			48
Net cash used in investing activities			(15,648	)			(14,837	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercises			14,200				1,976
Repurchases of common stock			(55,877	)			(50,827	)
Net cash used in financing activities			(41,677	)			(48,851	)
EFFECT OF EXCHANGE RATES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH			(1,512	)			(744	)
INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH			61,243				28,983
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — Beginning of period			277,766				131,920
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH — End of period		$	339,009			$	160,903

MEDPACE HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED)
(Amounts in thousands, except per share amounts)		Three Months Ended								Six Months Ended
		June 30,								June 30,
			2021				2020				2021				2020
RECONCILIATION OF GAAP NET INCOME TO EBITDA
Net income (GAAP)		$	39,934			$	24,104			$	83,240			$	53,058
Interest expense (income), net			27				5				41				(352	)
Income tax provision			2,752				6,258				7,955				13,782
Depreciation			3,951				2,674				7,763				5,127
Amortization			1,279				1,980				2,557				3,977
EBITDA (Non-GAAP)		$	47,943			$	35,021			$	101,556			$	75,592
Net income margin (GAAP)			14.3	%			11.8	%			15.5	%			12.2	%
EBITDA margin (Non-GAAP)			17.2	%			17.1	%			18.9	%			17.3	%

FY 2021 GUIDANCE RECONCILIATION (UNAUDITED)
(Amounts in millions, except per share amounts)		Forecast 2021
		Net Income								Net income per diluted share
		Low				High				Low				High
Net income and net income per diluted share (GAAP)		$	162.5			$	169.5			$	4.31			$	4.50
Income tax provision			20.2				23.2
Interest income, net			-				-
Depreciation			17.2				17.2
Amortization			5.1				5.1
EBITDA (Non-GAAP)		$	205.0			$	215.0

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005624/en/

FAQ

What were Medpace's Q2 2021 revenue figures?

Medpace reported Q2 2021 revenue of $278.3 million, a 35.8% increase from the prior year.

What is Medpace's backlog as of June 30, 2021?

As of June 30, 2021, Medpace reported a backlog of $1.7 billion, a 29.8% growth year-over-year.

How much was Medpace's net income for Q2 2021?

Medpace's GAAP net income for Q2 2021 was $39.9 million, or $1.06 per diluted share.

What is the book-to-bill ratio for Medpace in Q2 2021?

The net book-to-bill ratio for Medpace in Q2 2021 was 1.39x.

What revenue guidance did Medpace provide for 2021?

Medpace forecasted 2021 revenue between $1.110 billion and $1.150 billion.